RxDoctor Payments Data

Nancy Towbin, MD

Gynecology · Yorba Linda, CANPI 1235233222

Payments from drug & device makers

$2,732in general payments, 2019–2025

Across 50 payments — averaging $54.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hologic Sales And Service, LLC$1K
  • Myriad Genetic Laboratories, Inc.$250
  • Amgen$229
  • AbbVie$198
  • Acessa Health Inc.$112
  • Astellas Pharma US Inc$108
  • plus $348 from 7 others

What the payments were for

  • Travel & lodging$1,03738%
  • Food & beverage$1,59558%
  • Education$823%
  • Gifts$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,732 in reported general payments places this provider in the 70th percentile of 247 gynecology providers in California.

See all gynecology providers in California

Medicare billing

Part B allowed, 2024
$116,230
Medicare patients
550
Services billed
1,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab21$35,467
Estradiol (Twice Weekly)Estradiol291$30,792
PremarinEstrogens, Conjugated59$29,760
Estradiol337$23,293
MyrbetriqMirabegron20$21,112
ProgesteroneProgesterone, Micronized336$15,492
FemringEstradiol Acetate15$10,899
DottiEstradiol93$10,589
EstringEstradiol14$7,238
YuvafemEstradiol29$5,721
ImvexxyEstradiol17$5,630
LyllanaEstradiol38$4,997
SynthroidLevothyroxine Sodium52$4,422
Vivelle-DotEstradiol17$4,129
Estradiol (Once Weekly)Estradiol49$3,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$66$36,99773 claims
AmgenProlia$229$35,46721 claims
Astellas Pharma US IncMyrbetriq$108$21,11220 claims
AbbVieSynthroid, Armour Thyroid$198$5,51774 claims
BayerClimara$16$1,65014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 247 gynecology providers in California.

Other gynecology in Yorba Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →